From this perspective, DLBCL-NOS patients with the MCD subtype might be potential candidates for therapies targeting the BCR pathway and NF-κB signaling such as ibrutinib (Bruton tyrosine kinase inhibitor) or lenalidomide (immune modulator), respectively [7,42,43,44]. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.